focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.825
Bid: 1.80
Ask: 1.85
Change: -0.173 (-8.66%)
Spread: 0.05 (2.778%)
Open: 1.825
High: 1.85
Low: 1.825
Prev. Close: 1.998
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
17th Dec 20126:13 pmRNSDirector/PDMR Shareholding
13th Dec 20123:24 pmRNSResult of AGM
10th Dec 20129:45 amRNSHolding(s) in Company
7th Dec 20121:00 pmRNSCash Placing
21st Nov 20128:18 amRNSAnnual Report & Accounts and Notice of AGM
25th Oct 201210:54 amRNSHolding(s) in Company
24th Oct 201212:19 pmRNSHolding(s) in Company
24th Oct 20129:51 amRNSHolding(s) in Company
16th Oct 20127:00 amRNSFinal Results
4th Oct 20123:55 pmRNSDirector/PDMR Shareholding
10th Sep 20123:19 pmRNSPreliminary Results Date
6th Aug 20127:00 amRNSPre-Close Trading Update
3rd Aug 201211:58 amRNSProfessor Chris Potten
27th Jul 20124:09 pmRNSDirector's Shareholding and Additional Listing
10th Jul 20129:17 amRNSDirector/PDMR Shareholding
5th Jul 20127:00 amRNSTuberculosis test gains CE-IVD registration
3rd Apr 20124:53 pmRNSDirector/PDMR Shareholding
27th Mar 20129:13 amRNSAdditional Listing
14th Mar 20127:00 amRNSHalf Yearly Report
5th Mar 20127:00 amRNSEpistem Signs TB Channel Partner Agreement
22nd Feb 20128:18 amRNSHolding(s) in Company
21st Feb 20127:00 amRNSNotice of Results
20th Feb 20126:28 pmRNSHolding(s) in Company
10th Feb 20127:00 amRNSHolding(s) in Company
10th Jan 20121:18 pmRNSDirector/PDMR Shareholding
19th Dec 20115:54 pmRNSDirectors' shareholdings and issue of equity
25th Nov 201112:00 pmRNSCash Placing
9th Nov 20117:00 amRNS2011 Annual Report and Accounts & Notice of AGM
11th Oct 20117:00 amRNSFinal Results
7th Oct 201112:43 pmRNSDirector/PDMR Shareholding
5th Oct 20117:00 amRNSHuman DNA Identification Collaboration
27th Sep 20117:00 amRNSGenedriveT passes first in-field Tuberculosis test
4th Aug 20117:00 amRNSPre Close Trading Update
30th Jun 201112:00 pmRNSDirector/PDMR Shareholding
28th Jun 20117:00 amRNSTuberculosis Diagnostic Collaboration
23rd Jun 20114:38 pmRNSHolding(s) in Company
19th May 20115:20 pmRNSHolding(s) in Company
19th Apr 201112:32 pmRNSHolding(s) in Company
19th Apr 201112:28 pmRNSHolding(s) in Company
8th Apr 20119:20 amRNSHolding(s) in Company
5th Apr 20112:34 pmRNSDirector/PDMR Shareholding
4th Apr 201112:41 pmRNSHolding(s) in Company
4th Apr 20119:35 amRNSHolding(s) in Company
29th Mar 20117:00 amRNSDirector/PDMR Shareholding
29th Mar 20117:00 amRNSInterim Results
28th Mar 20119:47 amRNSHolding(s) in Company
17th Mar 20119:23 amRNSRe Agreement - Replacement
17th Mar 20117:20 amRNSRe Agreement
28th Feb 20111:22 pmRNSInterim Results Announcement
18th Feb 20114:26 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.